Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
SparingVision doses first patient in NYRVANA clinical trial of SPVN20 for retinitis pigmentosa | Ophthalmology Times
(Image Credit: AdobeStock/Davizro Photography) SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis pigmentosa (RP). NYRVANA is the first-in-human trial and is an open-label, multicenter, dose-escalation study investigating the safety, tolerability,…
Eli Lilly to acquire Adverum Biotechnologies | Ophthalmology Times
Image credit: AdobeStock/jozefmicic The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies. The companies noted that this definitive agreement will include Adverum’s lead candidate, Ixo-vec. Adverum and Lilly’s merger…
Positive phase 2 data for neoadjuvant darovasertib offers hope for unmet need in uveal melanoma | Ophthalmology Times
Image credit: AdobeStock/Christoph Burgstedt Positive results from the ongoing Phase 2 OptimUM-09 trial are encouraging for the treatment of uveal melanoma (UM). According to the press release from IDEAYA Biosciences, the developers of this therapeutic candidate, “there are currently no…
The future of glaucoma care: Where innovation meets everyday practice | Ophthalmology Times
Specialists in glaucoma care share insights on evolving strategies, technologies, and treatments shaping the future of patient management. (Image credit: AdobeStock) As glaucoma care continues to advance, ophthalmologists are embracing innovative technologies and new approaches that are reshaping diagnosis and…
New data from Sweden highlight lesion features that accelerate GA growth | Ophthalmology Times
(Image Credit: AdobeStock/Alexey Novikov) The lesion characteristics of patients with geographic atrophy (GA) were found to affect the lesion growth rate, with fovea-sparing, multifocal, and bilateral lesions having the fastest growth rates in a study published in Translational Vision Science…
Research supports that iron dysregulation may drive AMD | Ophthalmology Times
Image credit: AdobeStock/Gorodenkoff A new study supports the hypothesis that iron dysregulation may be a driver of dry age-related macular degeneration (AMD). This could be especially true in the early stage of geographic atrophy (GA). According to the research, the…
ONL Therapeutics randomizes first patient in phase 2 GALAXY trial evaluating xelafaslatide | Ophthalmology Times
(Image Credit: AdobeStock/Kirsten D) ONL Therapeutics announced the first patient has been randomized in its phase 2 GALAXY (NCT06659445) trial evaluating xelafaslatide (formerly ONL1204) in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD). According to the…
Bimatoprost drug pad-IOL system shows reduction in mean IOP at 24 months | Ophthalmology Times
Image credit: AdobeStock/oz Interim 24-month data from a trial of the bimatoprost drug pad-IOL system (BIM-IOL system) showed sustained improvements in intraocular pressure (IOP) and visual acuity outcomes.1 The BIM-IOL system has been developed by SpyGlass Pharma, Inc. The company…
Q&A: William F. Wiley, MD, on what BVI’s trifocal IOL approval means for US premium vision options | Ophthalmology Times
The FDA’s approval of the FineVision HP trifocal lens expands the range of premium lens option to US ophthalmologists and their patients. (Image credit: AdobeStock/Margarita Ratatosk) As the landscape of ophthalmic innovation continues to evolve, new technologies are reshaping how…
Evolving glaucoma therapy: A new era of interventional strategies | Ophthalmology Times
(Image Credit: AdobeStock/Yakobchuk Olena) Inder Paul Singh, MD, from The Eye Centers of Racine and Kenosha, Wisconsin, recently moderated an Ophthalmology Times Case-Based Roundtable that addressed the new playing field in glaucoma care. For Singh, the term interventional glaucoma no…